Cargando…

The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody)

Peptide display methods are a powerful tool for discovering new ligands of pharmacologically relevant targets. However, the selected ligands often suffer from low affinity. Using phage display, we identified a new bicyclic peptide binder of prostate-specific membrane antigen (PSMA), a metalloproteas...

Descripción completa

Detalles Bibliográficos
Autores principales: Blažková, Kristyna, Beranová, Jana, Hradilek, Martin, Kostka, Libor, Šubr, Vladimír, Etrych, Tomáš, Šácha, Pavel, Konvalinka, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600089/
https://www.ncbi.nlm.nih.gov/pubmed/34710374
http://dx.doi.org/10.1016/j.jbc.2021.101342
_version_ 1784601074561187840
author Blažková, Kristyna
Beranová, Jana
Hradilek, Martin
Kostka, Libor
Šubr, Vladimír
Etrych, Tomáš
Šácha, Pavel
Konvalinka, Jan
author_facet Blažková, Kristyna
Beranová, Jana
Hradilek, Martin
Kostka, Libor
Šubr, Vladimír
Etrych, Tomáš
Šácha, Pavel
Konvalinka, Jan
author_sort Blažková, Kristyna
collection PubMed
description Peptide display methods are a powerful tool for discovering new ligands of pharmacologically relevant targets. However, the selected ligands often suffer from low affinity. Using phage display, we identified a new bicyclic peptide binder of prostate-specific membrane antigen (PSMA), a metalloprotease frequently overexpressed in prostate cancer. We show that linking multiple copies of a selected low-affinity peptide to a biocompatible water-soluble N-(2-hydroxypropyl)methacrylamide copolymer carrier (iBody) improved binding of the conjugate by several orders of magnitude. Furthermore, using ELISA, enzyme kinetics, confocal microscopy, and other approaches, we demonstrate that the resulting iBody can distinguish between different conformations of the target protein. The possibility to develop stable, fully synthetic, conformation-selective antibody mimetics has potential applications for molecular recognition, diagnosis and treatment of many pathologies. This strategy could significantly contribute to more effective drug discovery and design.
format Online
Article
Text
id pubmed-8600089
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-86000892021-11-23 The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody) Blažková, Kristyna Beranová, Jana Hradilek, Martin Kostka, Libor Šubr, Vladimír Etrych, Tomáš Šácha, Pavel Konvalinka, Jan J Biol Chem Research Article Peptide display methods are a powerful tool for discovering new ligands of pharmacologically relevant targets. However, the selected ligands often suffer from low affinity. Using phage display, we identified a new bicyclic peptide binder of prostate-specific membrane antigen (PSMA), a metalloprotease frequently overexpressed in prostate cancer. We show that linking multiple copies of a selected low-affinity peptide to a biocompatible water-soluble N-(2-hydroxypropyl)methacrylamide copolymer carrier (iBody) improved binding of the conjugate by several orders of magnitude. Furthermore, using ELISA, enzyme kinetics, confocal microscopy, and other approaches, we demonstrate that the resulting iBody can distinguish between different conformations of the target protein. The possibility to develop stable, fully synthetic, conformation-selective antibody mimetics has potential applications for molecular recognition, diagnosis and treatment of many pathologies. This strategy could significantly contribute to more effective drug discovery and design. American Society for Biochemistry and Molecular Biology 2021-10-25 /pmc/articles/PMC8600089/ /pubmed/34710374 http://dx.doi.org/10.1016/j.jbc.2021.101342 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Blažková, Kristyna
Beranová, Jana
Hradilek, Martin
Kostka, Libor
Šubr, Vladimír
Etrych, Tomáš
Šácha, Pavel
Konvalinka, Jan
The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody)
title The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody)
title_full The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody)
title_fullStr The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody)
title_full_unstemmed The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody)
title_short The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody)
title_sort development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (ibody)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600089/
https://www.ncbi.nlm.nih.gov/pubmed/34710374
http://dx.doi.org/10.1016/j.jbc.2021.101342
work_keys_str_mv AT blazkovakristyna thedevelopmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT beranovajana thedevelopmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT hradilekmartin thedevelopmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT kostkalibor thedevelopmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT subrvladimir thedevelopmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT etrychtomas thedevelopmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT sachapavel thedevelopmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT konvalinkajan thedevelopmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT blazkovakristyna developmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT beranovajana developmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT hradilekmartin developmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT kostkalibor developmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT subrvladimir developmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT etrychtomas developmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT sachapavel developmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody
AT konvalinkajan developmentofahighaffinityconformationsensitiveantibodymimeticusingabiocompatiblecopolymercarrieribody